Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Titan Pharmaceuticals (TTNP) Share Price
Press coverage about Titan Pharmaceuticals (NASDAQ:TTNP) has been trending somewhat positive on Tuesday, Accern reports. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Titan Pharmaceuticals earned a news impact score of 0.08 on Accern’s scale. Accern also gave news stories about the specialty pharmaceutical company an impact score of 46.5784530462491 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
TTNP has been the subject of several research analyst reports. Roth Capital reiterated a “buy” rating and issued a $6.00 price objective on shares of Titan Pharmaceuticals in a report on Thursday, October 5th. ValuEngine lowered Titan Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st.
Shares of Titan Pharmaceuticals (TTNP) traded down $0.05 during trading hours on Tuesday, hitting $1.55. The stock had a trading volume of 158,900 shares, compared to its average volume of 147,313. Titan Pharmaceuticals has a 12-month low of $1.30 and a 12-month high of $4.80.
Titan Pharmaceuticals (NASDAQ:TTNP) last announced its earnings results on Thursday, November 9th. The specialty pharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.04). Titan Pharmaceuticals had a negative return on equity of 152.57% and a negative net margin of 4,481.82%. The firm had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.17 million.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company’s segment is engaged in the development of pharmaceutical products. The Company’s product development programs utilize its long-term drug delivery platform, ProNeura.
Receive News & Ratings for Titan Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.